Table 1.

Radiation courses and tumor characteristics of patients with baseline data (n = 702), complete treatment data (n = 516), and toxicity data (n = 415)

		n (%)*
Patients with baseline data	Total patients	702
	Patients with multiple courses	6†
Male		554 (79%)
Age, y‡		68 (22-93)
Good performance score§ (n = 384)		353 (92%)
Clinical indication	Primary tumor/tumor bed	491 (70%)
	Regional lymph nodes	110 (16%)
	Metastasis	70 (10%)
	Recurrence primary site	31 (4%)
Treatment intent	Curative	523 (75%)
	Palliative	164 (23%)
	Unknown	15 (2%)
Tumor sites treated		39
Patients per tumor site║	Prostate	281 (40%)
	Lymph nodes	117 (17%)
	Brain	85 (12%)
	Rectum	70 (10%)
	Liver#	33 (5%)
	Pancreas	29 (4%)
	Oropharynx	13 (2%)
	Lung	8 (1%)
	Esophagus	7 (1%)
	Bladder	6 (1%)
Patients with treatment Data	Total patients	516**
	Patients with multiple courses	6
Male		418 (81%)
Age, y‡		69 (25-93)
Good performance score§ (n = 244)		221 (91%)
Patients per tumor site	Prostate	223 (42%)
	Lymph nodes	106 (21%)
	Rectum	57 (11%)
	Liver#	30 (6%)
	Pancreas	21 (4%)
	Oropharynx	12 (2%)
	Brain	7 (1%)
Patients with toxicity Data	Total patients	415**
	Patients with multiple courses	5
Male		331 (80%)
Age, y‡		68 (25-93)
Good performance score§ (n = 287)		261 (91%)
Patients per tumor site	Prostate	167 (40%)
	Lymph nodes	92 (22%)
	Rectum	43 (10%)
	Liver#	27 (7%)
	Pancreas	19 (5%)
	Oropharynx	12 (3%)

^*Numbers (percentage) except where indicated.

^**For the treatments and toxicity data all courses were analyzed.

^†For clarity, the table only summarizes the characteristics of a patient’s first course within MOMENTUM, except where indicated.

^‡Frequencies given in median (range).

^§Good performance score defined as Karnofsky Performance Score (KPS) ≥80%, Eastern Cooperative Oncology Group (ECOG) score 0, or Charlson Comorbidity Index (CCI) score ≤2.

^║Total number of patients (%) for the 10 most frequently treated tumor sites.

^#The liver tumor site includes patients with cancers of the intrahepatic bile ducts.